DexCom, Inc. $DXCM Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 69.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 6,411 shares of the medical device company’s stock after selling 14,923 shares during the period. Oppenheimer & Co. Inc.’s holdings in DexCom were worth $425,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in DXCM. CVA Family Office LLC increased its position in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. ORG Partners LLC increased its position in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the last quarter. Spire Wealth Management increased its position in shares of DexCom by 113.8% during the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 305 shares during the last quarter. Aventura Private Wealth LLC acquired a new stake in shares of DexCom during the fourth quarter valued at about $43,000. Finally, Rothschild Investment LLC increased its position in shares of DexCom by 59.9% during the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 245 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the transaction, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.28% of the company’s stock.

DexCom Trading Down 0.5%

Shares of DXCM stock opened at $60.61 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The stock has a market capitalization of $23.39 billion, a P/E ratio of 25.90, a price-to-earnings-growth ratio of 1.04 and a beta of 1.40. The company has a 50 day moving average price of $65.10 and a 200 day moving average price of $66.29. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 earnings per share. Equities research analysts predict that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on DXCM shares. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a research report on Tuesday, March 24th. Canaccord Genuity Group set a $100.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Friday, May 1st. TD Cowen dropped their price target on shares of DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Piper Sandler reiterated an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.50.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.